

NOVADEL PHARMA INC  
Form 8-K  
September 16, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): September 12, 2005**

**NOVADEL PHARMA INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-32177**  
(Commission File No.)

**22-2407152**  
(I.R.S. Employer  
Identification No.)

**25 Minneakoning Road**  
**Flemington, New Jersey 08822**  
(Address of principal executive offices) (Zip Code)

**(908) 782-3431**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On September 12, 2005, NovaDel Pharma Inc. (the Company) issued a press release to announce that the Company would present at the ValueRich Small-Cap Financial Expo NYC (the Financial Expo) on September 14, 2005, in New York City. Dr. Gary Shangold, the Company's Chief Executive Officer, delivered a presentation at the Financial Expo on the Company's product development activities. The full text of Dr. Shangold's presentation is attached hereto as Exhibit 99.1 and the full text of the press release is attached hereto as Exhibit 99.2. The information furnished pursuant to this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed filed for purposes of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, unless otherwise expressly stated in such filing.

**Item 8.01. Other Events**

During the Financial Expo referred to in Item 7.01, the Company's Chief Executive Officer provided an update on the Company's product development activities, including information that the Company had conducted pre-IND meetings with the Food and Drug Administration relating to sumatriptan, zolpidem and ondansetron during the months of August and September 2005.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

- 99.1 Slide Presentation used at September 14, 2005 ValueRich Small-Cap Financial Expo NYC.
- 99.2 Press release dated September 12, 2005, titled NovaDel Pharma, Inc. to Present at the ValueRich Small Cap Financial Expo NYC.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovaDel Pharma Inc.**

By: /s/ Jean W. Frydman

Name: Jean W. Frydman  
Title: General Counsel

Date: September 16, 2005

---

**EXHIBIT INDEX**

<u>Exhibit</u>	<u>Description</u>
99.1	Slide Presentation used at September 14, 2005 ValueRich Small-Cap Financial Expo NYC.
99.2	Press release dated September 12, 2005, titled NovaDel Pharma, Inc. to Present at the ValueRich Small Cap Financial Expo NYC.